Pages that link to "Q73769165"

The following pages link to Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines (Q73769165):

Displaying 42 items.

• Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines (Q33269187) (← links)
• Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid (Q34786475) (← links)
• Bisphosphonate therapy in multiple myeloma: past, present, future (Q35013342) (← links)
• The anti-tumour activity of bisphosphonates. (Q35019664) (← links)
• Antitumor effects of bisphosphonates (Q35053955) (← links)
• Zoledronic acid (Zometa®) use in bone disease (Q35117725) (← links)
• Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours (Q35208161) (← links)
• New insights into the pathophysiology and management of bone disease in multiple myeloma (Q35591086) (← links)
• Targeting bone as a therapy for myeloma. (Q35603128) (← links)
• Zoledronic acid: a new parenteral bisphosphonate (Q35615235) (← links)
• Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options (Q35678932) (← links)
• The Medical Research Council Myeloma IX trial: the impact on treatment paradigms (Q35700723) (← links)
• A retrospective study of skeletal and disease-free survival benefits of zoledronic acid therapy in patients with multiple myeloma treated with novel agents (Q36449801) (← links)
• Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates (Q36498963) (← links)
• Randomized clinical trial of zoledronic acid in multiple myeloma patients undergoing high-dose chemotherapy and stem-cell transplantation. (Q36568586) (← links)
• Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. (Q37340505) (← links)
• DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine. (Q37619866) (← links)
• Can bisphosphonates improve outcomes in patients with newly diagnosed multiple myeloma? (Q37847337) (← links)
• The backbone of progress – preclinical studies and innovations with zoledronic acid (Q37847339) (← links)
• Bisphosphonates as antimyeloma drugs (Q37946695) (← links)
• Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities (Q38299932) (← links)
• miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies. (Q38476564) (← links)
• Pilot study on the use of zoledronic acid to prevent bone loss in allo-SCT recipients (Q38496996) (← links)
• Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts (Q38854653) (← links)
• Role of acetylcholine receptors in proliferation and differentiation of P19 embryonal carcinoma cells (Q40003906) (← links)
• A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma (Q40412742) (← links)
• Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis (Q40561379) (← links)
• Statins may potentiate bisphosphonates anticancer properties: a new pharmacological approach? (Q40584452) (← links)
• Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines (Q40586841) (← links)
• Analgesic efficacy of zoledronic acid and its effect on functional status of prostate cancer patients with metastasis (Q41864229) (← links)
• The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate (Q42465607) (← links)
• Mechanisms behind the anti‐tumour effects of zoledronic acid use in multiple myeloma (Q42873656) (← links)
• Evolving therapeutic role of bisphosphonates in multiple myeloma (Q43200640) (← links)
• Oxaliplatin (L-OHP) treatment of human myeloma cells induces in vitro growth inhibition and apoptotic cell death. (Q43991579) (← links)
• Synergistic growth inhibition of YM529 with biologic response modifiers (BRMs) in myeloma cells (Q44048554) (← links)
• Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma (Q44198069) (← links)
• Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma (Q44358655) (← links)
• Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt (Q44559365) (← links)
• The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide (Q44712370) (← links)
• Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect. (Q46491760) (← links)
• Acute tumor lysis syndrome triggered by zoledronic Acid in a patient with metastatic lung adenocarcinoma (Q46555291) (← links)
• Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells. (Q46706721) (← links)